Licence variation: spironolactone for acne in women
What the buyer wrote
NHS England required a supplier to apply for a major (type II) MHRA Marketing Authorisation variation for spironolactone. The variation is to add a new indication to the current licence (marketing authorisation) for treating acne in women. The Successful Supplier would need to prepare a dossier for the MHRA including a Risk Management Plan, apply for the licence variation, and if granted update their licence, Summary of Product Characteristics and patient information leaflet with the new indication and related data.
Bid for this and lost? There is a short window in which the decision can be questioned.
Awarded to
Supplier not named
Details
- What the buyer calls it
- Licence variation: spironolactone for acne in women
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- services
- Where
- in Yorkshire and The Humber
Who the buyer named
NHSE Commercial was the named contact on this notice.